Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, has announced the launch of ScienceCloud, a new SaaS-based information management and collaboration workspace. ScienceCloud advances collaborative drug discovery with a new generation of integrated applications built on a scalable, cloud-based scientific platform. With no software to manage and no hardware to maintain, ScienceCloud improves operational excellence in globally networked research, significantly reducing IT cost and effort.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65595-sciencecloud-software-by-accelrys-advances-collaborative-drug-discovery
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced its next-generation mobile strategy for the laboratory―to provide a flexible and secure mobile computing environment that effectively connects scientists, equipment and materials in today’s laboratories where an increasing number and variety of mobile devices, from smart phones to tablet computers, are in use. With over a decade of experience in pioneering paperless, mobile computing and wireless compliance capabilities in regulated laboratories, Accelrys will empower organizations to deploy purpose-built mobile applications in the lab from research to manufacturing, satisfying specific workflow requirements in accordance with Good Manufacturing Practice.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65931-accelrys-capture-drives-next-generation-mobility-in-the-laboratory
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced Accelrys Insight and Accelrys Insight for Excel, completing the roll-out of Accelrys’ next-generation cheminformatics suite and providing an interactive, collaborative environment for rapid and effective decision-making in drug discovery. Accelrys Insight and Accelrys Insight for Excel offer research scientists an entirely new way of accessing, visualizing and analyzing data that is locked in disparate locations across internal discovery teams and networked external partners, helping to lower long-standing barriers to bringing innovative therapeutics to market faster and more cost effectively.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62191-accelrys-insight-next-generation-decision-making-in-scientific-discovery
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
St. Jude Children’s Research Hospital, www.stjude.org, announced today the appointment of James R. Downing, M.D., as its new CEO, effective July 15, 2014. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital, which is leading the way the world understands, treats and defeats pediatric cancer and other catastrophic diseases. Downing’s primary focus immediately upon assuming the CEO office will be to oversee a new era of clinical, research and infrastructure expansion throughout the St. Jude global network. He succeeds Dr. William E. Evans, who is retiring from the position after 10 years and returning full time to his long-standing pharmacogenomics research program at St. Jude.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256651-st-jude-children-s-research-hospital-new-era-of-expansion-and-growth/
In a world demanding more innovation faster from every organization, Great Work: How To Make a Difference People Love (McGraw-Hill Professional), is a landmark guide released today to help people everywhere become the catalysts for positive change their organizations need. The book, by employee engagement expert David Sturt with the O.C. Tanner Institute, mixes inspiration and aspiration with scientific research and profound business insights to help people ideate, innovate and deliver meaningful contributions at work.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63145-great-work-book
In celebration of World Heart Day on September the 29th, Olives from Spain encourages customers to partake in their three olive-based recipes. As numerous scientific research has shown the benefits to maintaining a balanced diet, accompanied by regular physical exercise, can prevent certain heart diseases; we are delighted to provide these recipes.
As a natural source of vitamin E, olives have been at the forefront of the European gastronomic tradition and culture. The history of southern Europe is bathed in olive fields, a tree closely linked to the Mediterranean food.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8407151-olives-from-spain-recipes-world-heart-day/
Through thousands of hours meeting with women from Dallas to Taipei, Sao Paulo to Paris, Neutrogena® uncovered a universal truth – women are stepping back to examine what’s possible in their lives so they can pursue their dreams. Always on a mission to create, innovate, and rethink what’s possible in skincare, Neutrogena® identified this shared value and was inspired to launch its first-ever global campaign: “Neutrogena. See What’s Possible.™”
“Neutrogena® started as a dream, and through scientific discovery, creative thinking and the resilience to defy expectations without any compromises, a brand was born,” said Alicia Sontag, President, Beauty Care, Johnson & Johnson Consumer Inc. “We support women around the world and are proud to help them put their best face forward as they pursue their own dreams – big or small.”
The “Neutrogena. See What’s Possible™” campaign will debut with a commercial voiced by Brand Ambassador and creative consultant Kerry Washington which features real women following their passions. The empowering video brings to life the brand’s point of view on beauty – what really makes a woman beautiful is the ability to look in the mirror and know that anything is possible. In addition, educational and inspiring digital content designed to encourage her along her journey will be leveraged through social platforms in over 27 countries around the world, making this the largest digitally-driven campaign the brand has ever executed.
To view the multimedia release go to:
http://www.multivu.com/players/English/7770451-neutrogena-see-what-s-possible/
Subaru of America, Inc. today announced the completion of a Pet Travel Seat Pilot Study as part of its continued partnership with Center for Pet Safety (CPS), a registered 501(c)(3) non-profit research and consumer advocacy organization. Subaru and CPS have tested pet products most commonly used by pet parents when traveling. Phase one tested pet harnesses, phase two tested pet crates and carriers, and now, phase three has tested pet travel seats.
A pet travel seat is typically used in a vehicle to hold or elevate the pet, but does not offer full containment. The Pet Travel Seat Pilot Study found that while a pet travel seat may offer distraction prevention, it will likely not offer crash protection in the event of an accident, which could lead to injury of the pet and the human vehicle passengers. The quality of commonly available pet travel seats did not provide effective protection in a crash scenario.
Based on the scientific test evidence collected over the past four years, in part through its partnership with Subaru, CPS can now identify the safest travel options for most pets. For small dogs and cats, Center for Pet Safety recommends one of the 2015 Top Performing Carriers; for medium and large dogs either the 2015 Top Performing Crate - Gunner Kennels G1 Intermediate with 8' Tie Down Straps, or a Center for Pet Safety Certified Harness. To view top performing products and CPS Certified products, visit www.CenterforPetSafety.org.
To view the multimedia release go to:
http://www.multivu.com/players/English/7074158-subaru-cps-pet-travel-seat-study/
A decade ago Turtle Beach Corporation (NASDAQ: HEAR), a leading audio technology company for over 40 years, pioneered the console gaming headset category and is set to do so again in 2016 with its revolutionary Turtle Beach® Elite Pro Tournament Gaming Headset, Elite Pro Tactical Audio Controller (T.A.C.) and Elite Pro accessories designed for competitive gamers, which establishes a new standard for eSports gaming audio performance and comfort. Turtle Beach’s “Elite” series products represent the highest level in audio and build quality, and the all-new Elite Pro Headset, T.A.C. and Elite Pro accessories are the Company’s all-new line of competitive gaming audio gear created to meet the demands of today’s professional and aspiring pro teams and players.
The Elite Pro Headset’s journey began in 2013. Seeing the consistent growth and popularity of eSports, Turtle Beach launched a comprehensive scientific research program to deeply examine the needs of professional and hardcore gamers as it pertained to game audio, communicating with teammates, and overall comfort. The result is the all-new Elite Pro Tournament Gaming Headset – a ground-up redesign of the competitive gaming headset that brings to market multiple first-and-only innovations in the core mechanics of headset design, weight and fit. Not only does the Elite Pro Headset provide Turtle Beach’s best-in-class game audio and chat performance, but also delivers groundbreaking comfort-driven technologies, including the ComforTec® Fit System with multiple adjustment points for a truly personalized headset fit and feel, Aerofit® Ear Cushions that stay cool in the heat of battle, and Turtle Beach’s all-new patented ProSpecs® Glasses Relief System that finally makes wearing a gaming headset comfortable for players who wear glasses.
To view the multimedia release go to:
http://www.multivu.com/players/English/7537953-turtle-beach-optic-gaming-elite-pro/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
